These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38379328)

  • 41. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer.
    Chen W; Zhang J; Li F; Chen Z; Li J; Lu DL
    World J Surg Oncol; 2024 May; 22(1):126. PubMed ID: 38725003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
    Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
    Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of hormone receptor status on the efficacy of HER2-targeted treatment.
    Zhao B; Zhao H; Zhao J
    Endocr Relat Cancer; 2018 Jun; 25(6):687-697. PubMed ID: 29739815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study.
    Jiao D; Li G; Dai H; Wang J; Zhang J; Hou Y; Guo X; Zhao Y; Gong X; Liu Z
    Oncologist; 2024 Jul; 29(7):e877-e886. PubMed ID: 38537665
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
    Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
    Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
    Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
    Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
    Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterogeneity of genomic profile in patients with HER2-positive breast cancer.
    Chen B; Zhang G; Wei G; Wang Y; Guo L; Lin J; Li K; Mok H; Cao L; Ren C; Wen L; Jia M; Li C; Hou T; Han-Zhang H; Liu J; Balch CM; Liao N
    Endocr Relat Cancer; 2020 Mar; 27(3):153-162. PubMed ID: 31905165
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
    González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
    Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
    PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
    Ye Q; Qi F; Bian L; Zhang SH; Wang T; Jiang ZF
    Chin Med J (Engl); 2017 Mar; 130(5):522-529. PubMed ID: 28229982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.